Categories: News

Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call.

A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company’s website at https://ir.bioventus.com/. The webcast will be archived at the same site and available for replay until May 6, 2025.

About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Investor and Media Inquiries:
Dave Crawford
919-474-6787
Dave.Crawford@bioventus.com

Staff

Recent Posts

Smart Textiles Market worth $5.56 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- The smart textiles market is projected to grow…

49 minutes ago

Flow Cytometry Market worth US$9.85 billion in 2033 with 8.7% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- The global Flow Cytometry Market, valued at US$4.87…

49 minutes ago

Avantor® Reiterates Shareholder Value Creation Focus

Emmanuel Ligner, Seasoned Leader with Proven Track Record of Value Creation in Life Sciences, to…

49 minutes ago

Nordic and CLEAR partner to offer healthcare organizations a seamless, secure way to manage EHR accounts

MADISON, Wis., Aug. 11, 2025 /PRNewswire/ -- Nordic®, a global health and technology consulting company,…

49 minutes ago

Intas & Accord signs Agreement to acquire Prothya Biosolutions

AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals,…

49 minutes ago

EVERISE STRENGTHENS LEADERSHIP TEAM WITH CHIEF REVENUE OFFICER AND CHIEF FINANCIAL OFFICER APPOINTMENTS

PLANTATION, Fla., Aug. 11, 2025 /PRNewswire/ -- Everise, a global leader in transforming customer experiences,…

49 minutes ago